Insights into Pharma’s Next Big Shift from Swoop CRO Katie Carr 

It’s time to reassess the knee-jerk reaction of suppressing entire states from marketing campaigns and consider more sophisticated, compliant approaches to audience targeting.

At the intersection of data science, healthcare, and marketing lies a unique talent – Romain, Swoop’s Vice President of Product.

At Swoop, we’re not just redefining how healthcare marketers reach their audiences—we’re transforming the entire omnichannel experience.

Swoop Piper s transforming how pharma marketers interact with their data and accelerating decision-making processes.

Swoop’s thought leaders are sharing their valuable insight on what’s needed to thrive in 2025.

While it may seem more convenient to have one vendor create, manage, and measure outcomes, this approach can lead to an overestimation of performance.

Don’t miss this essential conversation about navigating the complex landscape of healthcare data privacy to make informed marketing strategy decisions .

R&D in rare diseases has skyrocketed. Thirty percent of today’s R&D pipeline is in rare diseases, and 40 percent of overall pipeline growth since 2013 is due to rare diseases.

Health care marketing is rapidly evolving, driven by AI, health privacy legislation, the need to reach more diverse patient communities, and the growth of direct-to-patient offerings. To help us sort the reality from the hype, we invited four brilliant partners from top pharma agencies to join a panel at our recent MyHealthTeam Summer Summit in NYC. Their candid, unfiltered observations are summarized below.

I believe in the power of data-driven omnichannel strategies, but so many in our industry don’t understand what matters: Connecting with the right audiences on the right channels.